New hope for hard-to-treat ovarian cancer: experimental drug BL-M07D1 enters final testing phase
NCT ID NCT07545460
First seen Apr 23, 2026 · Last updated May 15, 2026 · Updated 6 times
Summary
This study tests a new drug called BL-M07D1 against standard chemotherapy in about 404 people with HER2-positive ovarian, fallopian tube, or peritoneal cancer that no longer responds to platinum-based treatments. The goal is to see if BL-M07D1 can slow cancer growth or improve survival. Participants will be randomly assigned to receive either the new drug or a doctor-chosen chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY PERITONEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Contact
Conditions
Explore the condition pages connected to this study.